Jiangsu province will continue to deepen its cooperation with UK-based biopharma company AstraZeneca in biological medicine and medical internet of things.

Li Qiang, Party secretary of Jiangsu, meets with Pascal Soriot, CEO of AstraZeneca on Aug 15 in Nanjing, capital of Jiangsu province. [Photo/ jstv.com] 

The news was announced at a meeting between Li Qiang, Party secretary of Jiangsu, and Pascal Soriot, CEO of AstraZeneca on Aug 15 in Nanjing, capital of Jiangsu province. 

After introducing Jiangsu’s economic and social development conditions, Li said that the province boasts a sound manufacturing industry, an open economy, sufficient talent resources, and a good foundation and conditions for developing its medical industry. 

He added that the biomedical industry is a promising high-tech industry and is also one of the key emerging industries in Jiangsu. 

Li said that as a global leading science-led biopharmaceutical business, AstraZeneca has achieved remarkable progress in investment in Jiangsu and the government will continue to support its projects in Taizhou and Wuxi, and enhance the protection of its intellectual property rights. 

He also hoped to deepen cooperation with AstraZeneca in biological medicine and medical IoT.

Li Qiang (R) takes a photo with Pascal Soriot during their meeting on Aug 15 in Nanjing, capital of Jiangsu province. [Photo/ jstv.com] 

Soriot introduced AstraZeneca’s development conditions in Jiangsu and said that the company feels confident in Jiangsu. It will actively promote its cooperation with Jiangsu in medicine R&D and medical IoT by making full use of its advantages so as to create more cooperative results.